ArticleDiabetes2012
A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection.
Article in Diabetes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Immune modulation for β-cell replacement in type 1 diabetes.Frontiers in immunology · 2026Review
- Advancements and Challenges in Immune Protection Strategies for Islet Transplantation.Journal of diabetes · 2025Review
- Brown Adipose Tissue as a Unique Niche for Islet Organoid Transplantation: Insights From In Vivo Imaging.Transplantation direct · 2024Article
- Deep learning-enabled quantification of simultaneous PET/MRI for cell transplantation monitoring.iScience · 2023Article
- Synthesis of siRNA-Conjugated Dextran-Coated Iron Oxide Nanoparticles for Islet Protection During Transplantation and Noninvasive Imaging.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Engineered Extracellular Vesicles in Treatment of Type 1 Diabetes Mellitus: A Prospective Review.Biomedicines · 2022Review
- Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro.Stem cell reports · 2022Article
- Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines.Biomaterials advances · 2022Review
- Emerging Theranostic Nanomaterials in Diabetes and Its Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Artificial Intelligence Analysis of Magnetic Particle Imaging for Islet Transplantation in a Mouse Model.Molecular imaging and biology · 2021Article
- 3DFrontiers in cell and developmental biology · 2021Article
- Protection of Pancreatic Islets Using Theranostic Silencing Nanoparticles in a Baboon Model of Islet Transplantation.Diabetes · 2020Article
- Current Progress and Perspective: Clinical Imaging of Islet Transplantation.Life (Basel, Switzerland) · 2020Review
- Islet Transplantation Imaging in vivo.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
- Magnetic particle imaging of islet transplantation in the liver and under the kidney capsule in mouse models.Quantitative imaging in medicine and surgery · 2018Article
- Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Current diabetes reports · 2017Review
- Transgene and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus.Nano reviews & experiments · 2017Review
- Recent progress in the use and tracking of transplanted islets as a personalized treatment for type 1 diabetes.Expert review of precision medicine and drug development · 2017Article
- Diagnostic and prognostic utility of non-invasive imaging in diabetes management.World journal of diabetes · 2015Review
- Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.Molecular imaging and biology · 2014Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Islet transplantation has recently emerged as an acceptable clinical modality for restoring normoglycemia in patients with type 1 diabetes mellitus (T1DM). The long-term survival and function of islet grafts is compromised by immune rejection-related factors. Downregulation of factors that mediate immune rejection using RNA interference holds promise for improving islet graft resistance to damaging factors after transplantation. Here, we used a dual-purpose therapy/imaging small interfering (si)RNA magnetic nanoparticle (MN) probe that targets β(2) microglobulin (B2M), a key component of the major histocompatibility class I complex (MHC I). In addition to serving as a siRNA carrier, this MN-siB2M probe enables monitoring of graft persistence noninvasively using magnetic resonance imaging (MRI). Human islets labeled with these MNs before transplantation into B2M (null) NOD/scid mice showed significantly improved preservation of graft volume starting at 2 weeks, as determined by longitudinal MRI in an adoptive transfer model (P < 0.05). Furthermore, animals transplanted with MN-siB2M-labeled islets demonstrated a significant delay of up to 23.8 ± 4.8 days in diabetes onset after the adoptive transfer of T cells relative to 6.5 ± 4.5 days in controls. This study demonstrated that our approach could protect pancreatic islet grafts from immune rejection and could potentially be applied to allotransplantation and prevention of the autoimmune recurrence of T1DM in islet transplantation or endogenous islets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.